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Abstract.  After the cellular prion protein (PrP  c) 
transits to the cell surface where it is bound by a 
glycophosphatidyl inositol (GPI) anchor, PrP  c is either 
metabolized or converted into the scrapie isoform 
(Prpsc).  Because most GPI-anchored proteins are as- 
sociated with cholesterol-rich membranous microdo- 
mains, we asked whether such structures participate 
in the metabolism of PrP  c or the formation of PrP  sc. 
The initial degradation of PrP  c  involves removal of the 
NH2 terminus of PrP  c to produce a  17-kD  polypeptide 
which was found in a Triton X-100 insoluble fraction. 
Both the formation of PrP  s~ and the initial degradation 
of PrP  c were diminished by lovastatin-mediated deple- 
tion of cellular cholesterol but were insensitive to 
NI-LCI. Further degradation of the 17-kD polypeptide 
did occur within an NI-LCl-sensitive, acidic compart- 
ment. Replacing the GPI addition signal with the 
transmembrane and cytoplasmic domains of mouse 
CD4 rendered chimeric CD4PrP  c soluble in cold Tri- 
ton X-100.  Both CD4PrP  c and truncated PrP  c without 
the GPI addition signal (Rogers, M., E  Yehieley, M. 
Scott, and S.  B.  Prusiner.  1993.  Proc.  Natl.  Acad.  Sci. 
USA. 90:3182-3186)  were poor substrates for PrP  s¢ 
formation. Thus, it seems likely that both the initial 
degradation of PrP  c to the  17-kD polypeptide and the 
formation of PrP  s¢ occur within a  non-acidic compart- 
ment bound by cholesterol-rich membranes, possibly 
glycolipid-rich microdomains, where the metabolic 
fate of PrP  c is determined. The pathway remains to be 
identified by which the 17-kD polypeptide and PrP  s¢ 
are transported to an acidic compartment, presumably 
endosomes, where the 17-kD polypeptide is hydro- 
lyzed and limited proteolysis of PrP  s~ produces 
PrP 27-30. 
T 
HV. scrapie prion protein (prps¢) ' is the only known 
component of the transmissible prion (Bfieler et al., 
1993; Prusiner, 1991; Prusiner et al., 1993) and is de- 
rived from a normal cellular protein (PrP  c) which is bound 
to the surface of cells by a glycophosphatidyl inositol (GPI) 
anchor (Stahlet al., 1987).  In scrapie-infected cells in cul- 
ture, PrP  sc has been found to be derived from PrP  c mole- 
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cules by a posttranslational process that involves a change in 
the  conformation of PrP  c  without evidence for chemical 
modification (Staid et al., 1993). Spectroscopic studies have 
shown that PrP  c contains ~40%  c~-helix, and is devoid of 
B-sheet while PrP  s~ has more than 40 %/~-sheet (Pan et al., 
1993;  Safar et al.,  1993).  Upon conversion of PrP  c  into 
PrP  so, prion protein (PrP) molecules acquire new biochem- 
ical and biophysical properties that can be used as markers 
for identification. Whereas PrP  c is readily soluble in most 
detergent and is completely degraded by proteases, PrP  s~ is 
insoluble in detergents, possesses a protease-resistant core 
termed PrP 27-30  (Meyer et al.,  1986),  and po!ymedzes 
into amyloid designated prion rods (Prusiner et al., 1983). 
In scrapie-infected cells in culture, two mutually exclusive 
metabolic fates await plasma membrane prpc: (1) ~5% of 
PrP  c molecules are converted into PrP  s~ (Borchelt et al., 
1990;  Taraboulos et al.,  1990a)  and (2)  >90%  of PrP  c is 
degraded with a h/2  =  ,x,6 h  (Caughey et al.,  1989).  The 
subeellular sites for these two processes are unknown. The 
formation of PrP  sc is thought to require direct interaction 
between PrP  c and existing PrP  s~ molecules (Kocisko et al., 
1994;  Prusiner et al.,  1990).  Nascent PrP  s¢ is then NH2- 
terminally trimmed in an acidic compartment (Caughey et 
al.,  1991; Taraboulos et al.,  1992) and accumulates within 
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al.,  1990b).  Uninfected cells do not produce PrP  s~. 
Since understanding the metabolism of PrP  c is important 
in the study of prions, we have explored the influence of its 
GPI anchor on the two alternative metabolic fates described 
above.  GPI moieties are emerging as powerful sorting and 
targeting signals that direct proteins to specialized domains 
of the plasma membrane (PM) in various cell types. In par- 
ticular,  GPI-anchored proteins  seem  to  be  directed to  a 
membrane microenvironment (Simons and van Meer, 1988) 
that renders them insoluble in cold Triton X-100 (Brown and 
Rose, 1992; Cerneus et al., 1993; Cinek and Horejsi, 1992; 
Hooper and Bashir, 1991). Detergent insolubility is acquired 
in the Golgi apparatus and appears to remain a property of 
these proteins throughout their lifetime. When this property 
is lost during turnover processes is unknown. While the exact 
nature of these Triton X-100 insoluble membrane domains 
is unknown, they are thought to be considerably enriched in 
cholesterol and sphingolipids (Brown and Rose,  1992). 
Caveolae seem either to constitute a structurally and func- 
tionally specialized subset  of the Triton X-100  insoluble 
membrane domains, or to associate closely with them (An- 
derson et al., 1992). In cells possessing caveolae, the folate 
receptor,  PrP  c and other GPI-anchored proteins cluster in 
the vicinity of these PM invaginations (Ying et al.,  1992). 
However,  the  immunoelectron  microscopic  and  the  im- 
munofluorescence data supporting this caveolar clustering 
have recently been criticized on the ground that antibody 
cross-linking was  responsible  for some of this clustering 
(Mayor et al., 1994).  Cholesterol is necessary both for the 
structural  integrity of caveolae  and  their  only  currently 
known function, folate potocytosis (Anderson et al.,  1992; 
Anderson,  1993;  Chang  et  al.,  1992;  Rothberg  et  al., 
1990b). In one study, caveolae were identified on the surface 
of neuroblastoma (N2a) cells and quantitative immunocyto- 
chemistry of PrP  c revealed numerous clusters of gold parti- 
cles on the surfaces of these cells, 12 % of  which were in cav- 
eolae (Ying  et al.,  1992).  In contrast, other investigators 
failed to identify caveolae in N:a cells (Shyng et al., 1994). 
Because  there  is  disagreement  about  morphologically 
defined caveolae in N2a cells, our studies focused on mem- 
brane microdomains defined operationally by their insolubil- 
ity in Triton X-100 (Brown and Rose, 1992).  In addition to 
measuring the  Triton  X-100  insolubility of PrP  c  and its 
degradation products, we examined the cholesterol depriva- 
tion of cells and replacement of the GPI anchor of PrP with 
a transmembrane sequence. Upon analyzing the turnover of 
PrP  c,  we  unexpectedly found that degradation occurs  in 
two distinct steps. First, the polypeptide is NH2-terminally 
clipped  resulting  in  a  17-kD polypeptide (unglycosylated 
Mr) similar, or possibly identical, to prpc-II first identified 
in Syrian hamster (SHa) brain (Haraguchi et al., 1989; Pan 
et al.,  1992).  This degradative step occurs within Triton 
X-100 insoluble domains. Second, the 17-kD fragment was 
completely degraded within an acidic compartment which is 
likely to be endosomal. When cells were depleted of choles- 
terol, PrP  c degradation was slowed, and the generation of 
PrP  s~ molecules was inhibited. Under these conditions, the 
synthesis  of  PrP  c  proceeded  normally  or  was  even  in- 
creased. 
To examine the importance of the GPI anchoring of PrE 
we replaced the GPI addition signal with the transmembrane 
and cytoplasmic regions of mouse CD4 (Littman and Gett- 
ner, 1987) that target proteins to clathrin-coated pits (Keller 
et al.,  1992).  In contrast to GPI-anchored PrP  c, chimeric 
CD4PrP  expressed in ScN:a cells was equally soluble in 
Triton X-100 at 4°C and 37°C and was not converted into 
PrP  s~.  Deletion of the GPI addition signal at the COOH 
terminus of PrP was previously found to diminish but not 
abolish PrP  h  synthesis in  scrapie-infected neuroblastoma 
(ScN2a) cells (Rogers  et al.,  1993).  In addition, a patient 
with Creutzfeldt-Jakob disease has been identified who has 
an amber mutation at codon 145 resulting in the translation 
of truncated,  anchorless  PrP  molecules  some  of which 
formed PrP amyloid plaques (Kitamoto et al., 1993). Thus, 
the GPI anchor seems to be dispensable for the structural 
changes which occur during the formation of PrP  s~. 
The foregoing results suggest that a cholesterol-dependent 
pathway  related  to  the  membrane  microenvironment  of 
PrP  c is involved in the degradation of PrP  c and in the for- 
mation of PrP  s~. 
Materials and Methods 
Materials 
Cholesterol standard (965-25), lipid-cholesterol  rich supplements (L 4848), 
and mevalonic acid lactone (M 9627)  were from Sigma Chem. Co.  (St. 
Louis, MO). Lovastatin (a generous gift from Merck, Sharp, and Dohme 
research laboratories, West Point, PA) was saponified (Langan and Volpe, 
1986) before use. [3SS]Methionine  was from New England Nuclear (Bos- 
ton, MA). Reduced lipid FBS was first purchased from Sigma Chem. Co. 
(F 8895). When this product was discontinued we prepared reduced lipid 
FBS (Goldstein et al., 1983). Reagents for cell culture were purchased from 
the University of California San Francisco Cell Culture Facility (San Fran- 
cisco, CA), except the methionlne-free medium and the (3418 which were 
from GIBCO BRL (Gaithersburg, MD).  Tunlcamycin and phosphatidyl- 
inositol-specific phospholipase C  (PIPLC) (B.  Cereus) were from Boeh- 
ringer Mannheim Corp. (Indianapolis, IN). Protein A-Sepharose was from 
Pharmacia Biotech (Piscataway,  NJ).  All other chemicals and inhibitors 
were from Sigma Chem. Co. 
Cultured Cells 
N2a cells were obtained from the Amer. Tissue Culture Collection (Rock- 
ville, MD).  ScN2a  cells are the persistently infected clone as described 
(Butler et al., 1988).  Hamster brain (HaB) cells were derived from the cul- 
ture  of a  Syrian hamster (SHa)  brain as described (Taraboulos  et  al., 
1990a). ScN~a-MHM2 expressing the gene PrP-MHM2 were as described 
(Scott et al., 1992).  All the cells were grown and maintained at 37.5"C  in 
DME16 supplemented with 10%  FBS, except when specified otherwise. 
Cells transfected with CIMPrP in the pSPOX vector were grown in the same 
medium suppiemented with 1 g/ml G418.  Cells for the lovastatin experi- 
ments were set up according to the following standard format unless other- 
wise specified: On day zero, •1.5  ×  106 cells were seeded on 6-cm plates 
(Coming  Glass  Works,  Coming,  NY),  and  grown  for 2  d  in  regular 
medium. On day 2, the medium was replaced by fresh DME supplemented 
in some cases with 10% reduced lipid FBS (Goldstein et al., 1983) and 200 
#M mevalonate. When needed, lovastatin was added to 0.3 #M on day 2. 
On day 5, the medium was replaced with fresh medium containing identical 
supplements. The experiments were carried out on day 6,  except when 
specified otherwise. 
Antibodies 
R073 is an antiserum raised in a rabbit against SDS-PAGE purified SHaPrP 
2%30 which reacts with SHaPrE mouse (Mo) PrP, and MHM2PrP (Serban 
et al., 1990; Taraboulos et al., 1990b).  3F4 is a mAb raised against SHaPrP 
2%30  (Kascsak et al.,  1987),  Its epitope, (Meh09-Meht2) is present on 
SHa as well as on MHM2PrP, but not on the MoPrP gene (Rogers et al., 
1992).  Thus, the 3F4 mAb does not recognize the wild-type (wt) MoPrP 
in  ScN2a  ceils but  reacts with the products of the chimeric PrP genes 
MHM2PrP (Scott et al., 1992) and MHM2-CD4PrP. The mAb 13A5 was 
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and anti P3 are monospecific rabbit sera raised against the SHaprP peptides 
90-102,  142-174,  and 220-233,  respectively. 
Metabolic Radiolabeling and Inhibitors 
Confluent cells growing on 5-cm plates were rinsed three times with PBS 
and  incubated for 30 rain with methionine free DME16  medium (MF- 
DME). The medium was then replaced with fresh MF-DME supplemented 
with 0.5 mCi of [35S] L-methionine (New England Nuclear, Boston, MA) 
supplemented with 5 % of  the appropriate serum as indicated in each experi- 
ment. At the end of the labeling period, the cells were rinsed twice with 
ice-cold PBS, and then either lysed and processed for immunoprecipitation 
or chased in DME plus 10% FCS for the appropriate length of time. When 
needed, mevalonate was added throughout the pulse and chase. Inhibitors 
were added either to the pulse or the chase periods, or both, as necessary. 
Inhibitors used in the pulse period were also added to the methionine starva- 
tion period. 
Tunicamycin (5 mg/ml in DMSO) was freshly prepared for each experi- 
ment. Lovastatin was solubilized in EtOH, and then saponified with NaOH 
before its solubilization in water.  Mevalonate was dissolved in EtOH at 4 
#g/ml and stored at  -20°C. 
Triton X-IO0 Solubility Assay 
Assays for solubility in Triton X-100 were performed on ice in a cold room 
("~4°C). Cells growing on 5-cm plates were rinsed twice with ice-cold PBS, 
chilled on ice for 15 rain, and then lysed with 1-ml ice-cold Triton X-100 
lysis buffer (1% Triton X-100,  150 mM NaCI,  10 mM Tris-HC1,  pH 7.8) 
for 10 mih. The lysates were then split into two equal fractions and trans- 
ferred to 1.5-ml centrifugation tubes; one half was incubated at 37°C for 
5 rain while the other half was kept on ice. In some cases, aliquots of lysates 
were incubated with saponin (to a final concentration of 1%) for 10 rain on 
ice before ultracentrifugation. The lysates were then centrifuged at 30000 
rpm (39,000 g) for 30 rain in a TLA 100.3 rotor (Beckman Instrs., Fuller- 
ton, CA) at 2°C. The supernatant was then processed for immunoprecipita- 
tion (see next section) after the addition of sodium sarcosinate (Sarkosyl) 
(1% (vol/vol) final concentration). The pellets of the high speed centrifuga- 
tion were discarded. 
We found that prolonged ultracentrifugation was necessary to sediment 
quantitatively the Triton X-100 insoluble PrPC; this contrasts with work of 
others using different cells and assaying for Triton X-100  insolubility of 
different GPI-proteins (Brown and Rose, 1992).  Possible reasons for differ- 
ences in sedimentation of GPI-proteins in cold Triton X-100 are discussed 
in the Results section. Since Triton X-100 insoluble PrP  c could be detected 
only when the temperature of the lysates was kept under 4°C at all times, 
it was essential to perform the procedure on ice in the cold room. 
Cell Lysis and Immunoprecipitation 
The cells were processed for immunoprecipitation as described elsewhere 
(Taraboulos et al., 1992) with some modifications. Cells growing on 5-cm 
plates were lysed in cold lysis buffer (100 mM NaCI, 10 mM EDTA, 0.5% 
NP-40, 0.5 % sodium deoxycholate, 10 mM Tris-HCl, pH 7.8); this lysis was 
performed at room temperature and the insoluble material was removed by 
a  low-speed centrifugation for  10 s in an Eppendorf centrifuge at room 
temperature. Sarkosyl, PMSF and the relevant antiserum were added to 
final concentrations of 1%, 0.1 M, and 1 #l/ml, respectively, for immuno- 
precipitation of PrP  c.  For  the  purification of PrP  so,  the  lysates  were 
digested with proteinase K before guanidine thiocyanate (GdnSCN) denatu- 
ration and methanol precipitation. The methanol pellets were resuspended 
in 1 ml TNS (100 mM NaCI, 1% Sarkosyl, 10 mM Tris-HCl, pH 7.8); sup- 
plemented with 0.1 mM PMSF for immunoprecipitation. 
When needed, PrP  c was separated from PrP  sc by ultracentrifugation be- 
fore immunoprecipitation. 1% Sarkosyl and 0.1 M PMSF wore added to the 
lysate that was then centrifuged at 39,000 g, 1 h in a Beckman TL-100 cen- 
trifuge equipped with a  TLA-100.3  rotor to remove Prt se (Meyer et al., 
1986),  and the supernatant was used for immunopurification. The antibody 
(Ab) was then incubated overnight at 4°C. Protein A-Sepharose beads were 
then added to the lysate for a  1-h incubation at room temperature, and the 
inununoadsorbed proteins wore purified by rinsing in TNS buffer.  Protein 
A-Sepharose was used for all the rabbit sera as well as for 3F4, which binds 
well  protein  A.  For  13A5, an  additional  incubation  step  with  rabbit 
anti-mouse IgG serum (Sigma Chem. Co.) was added before the precipita- 
tion with protein A. 
SDS-PAGE and Autoradiography 
The imrnunopurified proteins were analyzed on 12% SDS acrylamide gels 
as previously described (Laemmli, 1970).  Radiolabeled proteins were de- 
tected by autoradiography on AR X-ray films (Kodak). In some cases, the 
radioactivity in the gels was quantified using a PhosphorImnger from Mo- 
lecular Dynamics (San Diego, CA). 
Cholesterol and Protein Determination 
Cells were lysed in lysis buffer,  and 20 #1 of the postnuclear supernatant 
was  used  for the  fluorogenic reaction which measures free cholesterol 
(Heider and Boyett, 1978).  The system was calibrated using a cholesterol 
calibration solution from Sigma Chem. Co. Excitation was at 325 nm and 
emission was monitored between 315  nm and 500 nm. Fluorescence was 
assayed in a spectrofluorimeter model LS 50 B (Perkin Elmer Corp., Nor- 
walk, CT). Total protein content of the cells was determined using the BCA 
kit from Pierce (Rockford, IL). 
Recombinant MHM2-CD4PrP Gene 
To construct the MHM2-CD4PrP, the transmembrane and cytoplasmic re- 
gions of CD4 (Littman and Gettner, 1987) were fused to the MHM2PrP- 
(del 231-254)  gene lacking the GPI attachment sequence (Rogers et al., 
1993).  First, PvuI and XhoI restriction sites were introduced in the CIM 
sequence by PCR using the mismatched primers CD1  (5' A  GGG GTG 
AAC  C.G_b_ T CQ  GTG  TTC  CTG  GCT)  resulting  in  the  mutations 
Gin3~:~Arg and Thr36s~Ser,  and CD2  (5' CTC  ATC  TGA ~  CTC 
GAG CCA CCT GCA) (the mismatched nucleotides are underlined). The 
polymerase chain reaction fragment was then restricted with PvuI and XhoI 
and  ligated  into  the  MHM2PrP(del  231-254),  yielding  with  MHM2- 
CIMPrP sequence, which was then introduced into the expression plasmid 
pSPOX (Scott et al.,  1992)  at the unique sites BglII and XhoI. MHM2- 
CIMPrP is referred to as CD4PrP throughout this article. 
N2a  and  SCNea  cells  were  transfected with  pSPOX-CD4PrP  using 
lipofectin (GIBCO BRL) used according to the manufacturer's instructions, 
and they were then selected and maintained with 1 mg/ml of G418. 
Western Blotting 
In some cases, PrP  sc from cells was concentrated by limited proteolysis 
followed by ultracentrifugation before Western blot analysis. This permitted 
the loading of an entire 9-cm plate-equivalent per lane of the SDS-PAGE, 
resulting in an increase in the sensitivity of PrP  sc detection. One ml of lysis 
buffer was added to the cells on a 9-cm plate and the postnuclear supernatant 
was digested with proteinase K (50 #g/ml, 37°C, 1 h). Sarkosyl and PMSF 
were added to final concentrations of 1% and 0.1 raM, respectively, and 
the samples centrifuged at 57,000 g, 1 h, 4°C. The pellets were solubilized 
in 100 #1 containing 3 M of GdnSCN and 1% Sarkosyl; after incubating 
the samples at 65°C for 5 h, the GdnSCN was then removed by EtOH 
precipitation before loading the SDS-PAGE. 
Immunofluorescence 
For the immunofluorescent detection of cell surface PrP, cells growing on 
Permanox slides (Nunc, Inc., Naperville, IL) were incubated with the rele- 
vant Ab (1:50 of either antiserum or ascitic fluid) for 2 h at 4oc in PBS sup- 
plemented with reduced lipid FBS. For detection of MoPrP endogenous to 
the N2a cells, we used the rabbit antiserum R073.  For the detection of 
CD4PrE we used the rnAb 3F4 (Kascsak et al.,  1987) ascitic fluid. After 
rinsing with ice-cold PBS, the cells were fixed (10% formalin in PBS, 4°C, 
30  rain),  in appropriate cases permeahilized (0.1%  Triton X-100,  RT,  5 
min), and incubated for 30 min in 1% NH+C1 in PBS to quench the alde- 
hydes. The cells were then blocked in 5% milk in PBS, incubated with a 
fluorescein isothiocyanate-labeled anti-rabbit or anti-mouse IgG for 3F4 
and R073, respectively, for 30 min under the same conditions as the primary 
Ab, rinsed, and finally mounted in propyl gallate (Giloh and Sedat, 1982). 
Results 
Metabolism and Degradation of  PrP  c 
The degradation of PrP  c  and formation of PrP  s~ in ScN2a 
cells  are  mutually  exclusive  fates  experienced  by  plasma 
membrane PrP  c molecules. We first examined the turnover 
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soluble microdomains. To dissect the pathway of PrP  c deg- 
radation,  we used pulse-chase radiolabeling  experiments. 
ScN2a cells were radiolabeled for 2 h, and then chased for 
the indicated period of time, and PrP  c (the detergent solu- 
ble PrP) was immunoprecipitated with the polyclonal antise- 
rum  R073  and  analyzed by  SDS-PAGE  (Fig.  1  A).  The 
33-35-kD band was degraded with a t1/2 of several hours, as 
previously described (Borchelt et al., 1990; Caughey et al., 
1989). when NI-LC1 (40 raM) was added to the pulse and 
the chase media, a lower (Mr =  26-29 kD) band appeared 
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Figure 1. Degradation of PrP  c. (.4) ScN2a cells were radiolabeled 
for 2 h and chased for 0, 2, 4, 6, 10, or 24 h. (B) ScN2a  cells were 
both radiolabeled for 2 h and chased for the same times as in A in 
the presence of 40/~M NI-hC1. After lysis, the cells were cen- 
trifuged at 57,000 g for 1 h at 4°C to sediment PrP  so. PrP  c was 
immunoprecipitated  from the  supernatant  using  the  polyclonal 
R073 antiserum.  (C) Hail cells were radiolabeled for 1 h in the 
presence of tunicamycin (5/~g/ml), and chased for 0, 1, 2, 3, 4, or 
5 h. Cellular PrP  c was then immunoprecipitated with R073. The 
17-kD band is marked by an arrow and the 26-kD band by an arrow- 
head. (D) NI~CI (40 izM) was added throughout the pulse and the 
chase. In the NI-hCl-treated cells, the 17-kD degradation product 
(arrow) accumulated during longer chases. (E) Radioactivity in the 
PrP bands of HaB cells in C treated with tunicamycin quantified 
with a Phosphorlmager scanner. (F) Radioactivity in the PrP bands 
of HaB  cells  in D  treated  with  both  tunieamycin and  NI-hCI. 
(Closed circles) 26 kD PrP. (Open circles) 17 kD PrP. 
after 2 h of chase (Fig.  1 B). The increase in the 26-29-kD 
band correlated with the decrease in the 33-35-kD band, 
suggesting that this lower band is a degradation product sta- 
bilized by NI-hC1. 
To reduce the heterogeneity in the Mr of the PrP bands, 
which obscured their identity, we used tunicamycin. In both 
ScN2a cells (not shown) and SHa brain cells (Fig.  1, C and 
D), unglycosylated PrP  c was rapidly degraded to a  17-kD 
product (arrow). HaB cells were used in order to take advan- 
tage of the ot-PrP mAbs and ct-PrP peptide monospecific an- 
tisera (Barry et al., 1988; Rogers et al., 1991) in the mapping 
of this 17-kD degradation intermediate. HaB cells were ra- 
diolabeled for I h in the presence of 5 #M tunicamycin and 
chased for increasing periods of time ranging from 0 to 5 h 
(Fig.  1, C and D). Samples were lysed and PrP  c immuno- 
precipitated with R073  antiserum followed by SDS-PAGE. 
To ensure that all degradation fragments are detected, we ini- 
tially used the R073 polyclonal antiserum which was raised 
against PrP 27-30 (Serban et al.,  1990). The radioactivities 
in each of the PrP bands was quantified by phosphorimaging 
(Fig.  1, E  and F).  Unglycosylated PrP  c (the 25-kD band, 
arrowhead) was rapidly degraded while the 17-kD product 
(arrow) was degraded more slowly (Fig. 1, C and E). When 
NI-LCI was added to both the pulse and chase periods, the 
17-kD polypeptide increased with a concomitant decrease in 
the 26-kD band, suggesting a precursor-product relationship 
between  these  two  PrP  forms  (Fig.  1,  D  and  F).  That 
NI-LCI prevented the degradation of the 17-kD polypeptide 
is  reminiscent  of the  inhibition  by  NI-LC1 of the  NH2- 
terminal digestion of PrP  s" to form PrP 27-30 (Taraboulos 
et al., 1992). It seems likely that both the degradation of the 
17-kD polypeptide and the production of PrP 27-30 occur in 
an acidic compartment of the endosomal pathway. 
In ScN2a cells not treated with tunicamycin (Fig.  1 A), 
the 26-29-kD degradation product probably corresponds to 
the unglycosylated 17-kD  polypeptide. While NI-LCI pre- 
vented degradation of the  17-kD polypeptide, the degrada- 
tion of full-length PrP  c was similar whether or not NI-LCI 
was present in the cell medium (Fig.  1, B and D). Scrapie 
infection did not alter the degradation of PrP  c as assessed 
in  studies  comparing  uninfected N2a  and  infected ScN2a 
cells (not shown). 
To map the 17-kD fragment, we used a panel of ot-PrP pep- 
tide monospecific antisera and ot-PrP mAbs directed against 
SHaPrP (Fig. 2 A). while the full-length 26-kD band (Fig. 
2 B, arrowhead)  was immunoprecipitated with all the Abs, 
the  17-kD  degradation  intermediate  (arrow)  reacted  only 
with Abs directed against epitopes situated in the COOH- 
terminal portion of  the molecule (Fig. 2 B) including epitope 
P3  at  the  COOH  terminus  of the mature protein.  These 
results argue that the 17-kD product is generated by cleavage 
between the 3F4 and the 13A5 epitopes, i.e., between amino 
acids 111 and 138 of MoPrP or 112 and 139 of SHaPrP, and 
consists of the COOH-terminal portion of PrP  c (Fig. 2 A). 
A cleavage site in the corresponding region of the chicken 
PrP has been reported (Harris et al.,  1993). We conclude 
that the first step in PrP  c degradation involves the hydroly- 
sis of the ,~,90 NH2-terminal residues which are removed in 
a  NI-LCl-insensitive process.  The  remaining  17-kD  frag- 
ment  is  stabilized  by  NI-LC1 and  its  degradation  is  thus 
likely to take place in an acidic, presumably endocytic com- 
partment. These results argue that the 17-kD polypeptide is 
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of PrP  c.  (A) Linear map of SHaPrP showing the location of sev- 
eral epitopes.  The hatched  bar denotes  the  17-kD intermediate 
identified in R  (B) HaB cells were labeled for 4 h with tunicamycin 
and NI-hC1, and PrP  c was immunoprecipitated  with the following 
Abs: ~xP1 (lane 1), 3F4 (lane 2),  13A5 (lane 3), c~P5 (lane 4), and 
otP3 (lane 5). The 17-kD  band (arrow) reacted with 13A5, otP5, and 
otP3 but not with otP1 and 3F4, whereas the 26-kD band (arrow- 
head) reacted with all Abs. 
the same as or very similar to the NH2 terminally truncated 
PrP  c found in purified fractions from SHa brain which we 
earlier designated prpc-II (Haraguchi et al.,  1989;  Pan et 
al.,  1992). 
NH2-Terminal  Degradation of  PrP  c Occurs within 
Triton X-IO0 Insoluble Domains 
The removal of the NH2 terminus of PrP  c is an important 
metabolic event since  it probably renders  PrP  c  ineligible 
for conversion to PrP  s~. To characterize the subcellular site 
of this proteolytic process, we analyzed the solubility of both 
the precursor and product after treatment with Triton X-100. 
ScN2a cells treated with NILC1 (40/zM) were radiolabeled 
for 2  h,  and then either harvested immediately (Fig.  3 A, 
lanes 1-4) or chased in unlabeled medium (lanes 5-8). The 
cells were lysed in 1% Triton X-100 either at 4°C (lanes 1, 
2, 5, and 6) or at 370C (lanes 3, 4, 7, and 8) and centrifuged 
at 39000 g for 1 h at 2°C. PrP was immunoprecipitated from 
the  supernatant  using  R073  antiserum.  Both  full-length 
PrP  c  and  the  17-kD  degradation  intermediate  displayed 
similar differential solubility in Triton X-100  suggesting a 
similar membrane microenvironment for both these PrP spe- 
cies. To determine if similar results would hold for the un- 
glycosylated PrP  c,  we radiolabeled ScN2a cells for  1 h  in 
the presence of tunicamycin (Fig. 3 B), and then chased them 
l~gure 3.  PrP  c degradation  occurs  within cholesterol-rich  rafts. 
(A) ScN2a cells were radiolabeled for 2 h. In lanes 5-8, the cells 
were then  chased  in unlabeled  medium  for an additional  18 h. 
NtGCl  (40  /~M) was  present  during  the  pulse  and  the  chase 
period. The cells were then lysed in 1% Triton X-100 at either 4°C 
(lanes 1, 2, 5, and 6) or 37°C (lanes 3, 4,  7, and 8). The lysates 
were centrifuged at 39,000 g for 1 h at either 2*(2 (cells lysed at 
4°C) or at 25°C (cells lysed at 37°C). PrP was immunoprecipitated 
from the supematant using R073 antiserum.  (B) ScN2a cells were 
radiolabeled for 1 h in the presence of tunicamycin (20 tiM) and 
chased for 0, 1, 2, or 3 h.  (lanes 1 and 2, 3 and 4, 3 and 6, and 
7 and 8, respectively.) NI-hC1 (40/,M) was included during both 
the pulse and the chase periods. The cells were lysed in 1% Triton 
X-100 either at 4°C (odd-numbered lanes) or at 37°(2 (even-num- 
bered lanes), centrifuged and analyzed as described  for panel A. 
for increasing periods of times ranging from 0 to 3 h. The 
cells were then extracted with 1% Triton X-100 at either 4°C 
or 37°C, spun as before, and PrP  c was immunoprecipitated 
from the supernatant. Both the 26-kD band (arrowhead) and 
the 17-kD band (arrow) were almost insoluble at 370C sug- 
gesting  their  association  with  cholesterol-rich  complexes. 
Using PIPLC, we also found that the degradation intermedi- 
ate is GPI linked to membranes (data not shown). 
The initial step in PrP  c degradation appears to take place 
within a Triton X-100 insoluble, presumably cholesterol-rich 
microenvironment.  Whether  PrP  s~  is  also  formed  within 
a similar environment remains to be established.  Sedimen- 
tation in cold Triton X-100 cannot be used to appraise the 
association  of  PrP  s~  with  these  microdomains,  because 
PrP  sc is insoluble  in  non-denaturing  detergents  (Meyer et 
al.,  1986). 
Lovastatin Diminishes PrP  c Degradation 
To investigate the influence of cholesterol depletion on PrP  c 
degradation,  we compared N2a and ScN2a cells treated ei- 
ther with or without 0.3 ~M lovastatin for 4 d (Fig. 4). The 
cells were radiolabeled for 1 h in the presence of tunicamycin 
(20  ftM),  and  PrP  c  was  immunopurified  after increasing 
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(A) N2a and (B) ScN2a ceils grown in reduced lipid medium with- 
out  (odd-numbered lanes)  or  with  lovastatin  (0.3 #M)  (even- 
numbered lanes) were pulse radiolabeled for 1 h in the presence of 
tunicarnycin (20 #g/ml), and then chased for 0 (lanes I and 2),  1 h 
(lanes 3 and 4), 2 h (lanes 5 and 6), 3 h (lanes 7 and 8), or 4 h 
(lanes 9 and 10). PrP  c was then immunoprecipitated and analyzed 
by SDS-PAGE. 
periods of chase ranging from 0 to 4 h and analyzed by SDS- 
PAGE.  The  rate  of PrP  c  degradation  was reduced  in  the 
lovastatin-treated cells.  Whether  decreased degradation of 
PrP  c  is  a  consequence  of disrupting  cholesterol-rich  do- 
mains on the plasma membrane or results from a delayed ex- 
port of PrP  c to the cell surface remains to be determined. 
Lovastatin Reduces PrP  sc Synthesis 
Since lovastatin diminished the degradation of PrP  c, we de- 
termined whether depriving cells from cholesterol interfaces 
with the synthesis of prps%  ScN2a cells were plated at low 
density  (ca.  5  x  1@ cells per 5-cm dish)  in DME16  sup- 
plemented with lipid deficient FBS. Lovastatin was added at 
concentrations  of 0.1, 0.3,  1,  or  3  /~M  to  inhibit  cellular 
sterols synthesis; with the two highest lovastatin concentra- 
tions, cytopathology was considerable after 5 d. Cells were 
lysed  and  PrP  s~  analyzed  by  Western  immunoblotting  of 
proteinase K digested lysates. PrP  s~ content decreased with 
increasing lovastatin concentration (not shown).  A  concen- 
tration of 0.3 #M lovastatin was chosen for subsequent ex- 
periments because it reduced the amount of PrP  s~ while be- 
ing only minimally cytopathic. 
To explore the effect of cholesterol, depletion on PrP  s~, we 
incubated  ScN2a  cells  for 4  d  in  a  variety of conditions: 
normal  FBS  (Fig.  5,  lane  1),  normal  FBS  and  0.3  #M 
Figure  5.  Lovastatin  reduces  PrP  s~  synthesis  in  ScN2a cells. 
(Lanes 1-5 [Immunoblots]) ScN2a ceils were grown for 4 d with 
normal FBS (lane 1 ), normal FBS and 0.3 #M lovastatin (lane 2), 
reduced fat FBS and 0.3 #M lovastatin (lane 3), reduced fat FBS 
(lane 4), or reduced fat FBS and 0.3 #M lovastatin supplemented 
with 2.5  #g/ml cholesterol  (lane 5).  They were then lysed,  sub- 
jected to proteolysis  catalyzed  by proteinase  K (50 #g/ml,  1 h, 
37°C),  and analyzed by SDS-PAGE. Western immunoblots were 
probed with the polyclonal Ab R073. PrP  s~ was reduced  in cells 
treated  with lovastatin in reduced  fat serum when no exogenous 
cholesterol  was added.  (Lanes  6--8 [Autoradiographs])  PrP  c  in 
ScN:a cells were grown for 4 d with reduced fat serum. In lane 6, 
no other chemical was added, whereas the cells in lane 7were sup- 
plemented with lovastatin (0.3 ttM),  and in lane 8 both lovastatin 
(0.3 #M) and cholesterol (2.5 #g/ml) were added to the medium. 
The ceils were then metabolically radiolabeled for 2 h, lysed, im- 
munoprecipitated  with R073, and analyzed by SDS-PAGE. 
lovastatin (lane 2), reduced lipid FBS and 0.3/~M lovastatin 
(lane 3), reduced lipid FBS and lovastatin with the addition 
of cholesterol  (2.5  #g/ml,  lane 4)  and reduced lipid FBS 
(lane 5). Mevalonate (200 #M) was included in the medium 
of all samples to provide for non-sterol pathways, such as 
protein  isoprenylation.  Western  immunoblots showed that 
protease-resistant PrP  s~ was  reduced  in  cells  treated  with 
lovastatin in the presence of reduced fat FBS (Fig. 5, lane 3) 
in which cellular free cholesterol was reduced by 30%. Ad- 
dition  of  cholesterol  throughout  the  lovastatin  treatment 
prevented the  decrease  in  PrP  s~ (Fig.  5,  lane  4),  arguing 
that the inhibition of PrP  s~ was caused by the depletion in 
cholesterol rather than in other mevalonate metabolites. 
The synthesis of PrP  s~ in lovastatin-treated cells was also 
studied in pulse-chase metabolic radiolabeling experiments, 
in which cells were labeled for 2 h and chased for 7 h before 
PrP  s~  analysis  (data  not  shown).  These  experiments  also 
showed  that  PrP  s~  synthesis  was  reduced  in  lovastatin- 
treated cells.  In contrast,  Pr~  synthesis was unaltered  by 
lovastatin (Fig.  5,  lanes 6-8).  ScN2a cells were grown for 
4  d under conditions similar to those described above for the 
immunoblotting experiments and radiolabeled for 2 h  with 
[3sS]methionine.  After  lysis,  PrP  immunopurified  before 
SDS-PAGE and autoradiography (Fig. 5, lanes 6-8).  Since 
no detectable radiolabeled PrP  s~ is produced in ScN2a cells 
within this time frame (Borchelt et al.,  1990,  1992), we did 
not  separate radiolabeled  PrP  c  from unlabeled  PrP  s~.  In- 
terestingly, not only did PrP  c not decrease, but it often in- 
creased in cells treated with lovastatin and low-fat serum, as 
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contrast,  less PrP  c  could be released by PIPLC from the 
surface of the lovastatin-treated ceils,  suggesting that PrP  c 
might not be available for conversion into PrP  s¢ in choles- 
terol-depleted cells (data not shown). Whether this is due to 
the inaccessibility of cell surface PrP  c to PIPLC, to a  re- 
duced export of the protein to the plasma membrane, or to 
the increased partition of PrP  c into internal recycling com- 
partments in cholesterol-deprived cells remains to be deter- 
mined.  Delays in export of PrP  c to the plasma membrane 
could  result  in  decreased  PrP  sc  formation,  since  it  was 
shown earlier with PIPLC-releasable PrP  c is the precursor 
to PrP  s~ in ScNza cells (Borchelt et al.,  1992; Caughey and 
Raymond, 1991).  In contrast to these results with PrP  c, the 
pool of intracellular folate receptor was diminished, rather 
than increased, in lovastatin-treated MA104 cells (Chang et 
al.,  1992). 
Transmerabrane Anchorage Inhibits PrP  sc Formation 
To appreciate better the role of the cholesterol-rich microdo- 
mains in the metabolism of GPI-anchored PrP  c, we sought 
to  uncouple  PrP  c  from this  microenvironment by replac- 
ing  the  GPI anchor  by  a  transmembrane fragment.  Data 
from a previous study suggested that the GPI anchor is dis- 
pensable for the structural changes that occur in PrP  s~ for- 
Figure 6.  Expression  of CD4PrP in ScN2a cells.  (.4) Map of the 
MHM2PrP and CD4PrP constructs. (Full bar) GPI attachment se- 
quence. (Hatched bar) Transmembrane and cytoplasmic sequences 
from MoCIM. (B) ScN2a cells (lanes 1, 3, 5, and 6) and ScN2a 
cells transfected with the CIMPrP construct (lanes 2, 4, 6, and 8) 
were analyzed for PrP  c 0anes 1 and 2) and PrP  s¢ (lanes 3-8) by 
Western immunoblotting using R073 (lanes 1, 3, 5, and 6) or 3F4 
(lanes 2, 4, 7, and 8). In lanes 5-8, PrP  s~ was concentrated as fol- 
lows: 1 ml lysates from a 9-cm plate were subjected to proteolysis 
(20 #g/ml proteinase K, 37°C,  1 h) followed by a high-speed spin 
to purify PrP  s¢, and a whole plate equivalent was loaded in each 
lane. 20 #1 of the lysates were centrifuged (57,000 g, 1 h, 4°C) to 
separate  PrP  c  from prps~; supernatants  were loaded on lanes  1 
and 2 and pellets loaded on lanes 3 and 4.  ScN2a ceils transfected 
with  CD4PrP  did  not  synthesize appreciable  amounts  of CD4- 
PrP  s¢ (lanes 4 and 8). 
mation (Rogers et al.,  1993);  we constructed a hybrid PrP 
gene in which the GPI attachment signal was replaced with 
the  putative  transmembrane  and  cytoplasmic  regions  of 
mouse CIM (Fig. 6 A) (Littman and Gettner, 1987). Proteins 
anchored  through  this  CD4  fragment cluster  on clathrin- 
coated pits rather than on uncoated regions of the plasma 
membrane (Keller et ai., 1992). To construct the hybrid PrP, 
we employed the  chimeric MHM2PrP  gene (Scott et al., 
1992) which carries a  SHa-specific PrP epitope recognized 
by the 3F4 mAb (Kascsak et al.,  1987) (Fig. 6 A). This con- 
struction permitted us to discriminate the CD4MHM2PrP 
from the  endogenous  MoPrP  in  ScN2a  cells.  Introduction 
of the  3F4  mAb  epitope  (Metl08-MetiH)  did  not  prevent 
PrP  s~  formation  when  introduced  into  the  GPI-anchored 
MoPrP (Rogers et al.,  1991;  Scott et al.,  1992). 
We transfected ScN2a cells with the  recombinant CD4- 
PrP gene and used an uncloned cell population in the subse- 
quent  experiments,  which  was  selected by an  addition  of 
G418  to the  cultures.  Western  immunoblotting  developed 
with 3F4 confirmed that transfected ScN2a cells synthesized 
CIMPrP  c  (Fig.  6  B,  lane 2).  As  expected,  the Mr of this 
CD4PrP  c  was  slightly  larger  than  that  of GPI-anchored 
wtPrP (lane 1 ). To determine whether CD4PrP can be con- 
verted  into  PrP  s~,  the  CD4PrP  construct  was  transfected 
into ScN2a ceils (lanes 3-8). No 3F4 reacting PrP  s~ signal 
could be detected in transfected ScN2a cells (lane 4) while 
the  control  ScN2a  cells were positive with the  polyclonal 
Ab R073, which recognizes wtPrP (lane 3). To increase the 
sensitivity  of PrP  s~  detection  in  cell  lysates,  we  concen- 
trated PrP  s~ ~50-fold by proteolysis followed by ultracen- 
trifugation.  In the transfected cells lane,  only a  very faint 
protease-resistant signal could be detected with 3F4,  even 
when the lysate from an entire 9-cm dish was loaded onto 
a single lane (Fig. 6, lane 8). This signal was specific for the 
3F4  epitope since a  lysate from untransfected ScN2a cells 
yielded no immunoreactive band with this Ab (lane 7). Since 
our assay is based on the host cells being persistently in- 
fected, thereby providing endogenous prions necessary for 
the  synthesis  of PrP  so,  we used  the  polyclonal antiserum 
R073 to confirm that these ScN2a cells were still synthesiz- 
ing MoPrP  s~ at the same level as the original ScN2a popula- 
tion (lanes 5  and 6). 
We  also  compared the  internalization  patterns  of GPI- 
anchored wtPrP and CD4PrP (Fig. 7). ScN2a cells were la- 
beled at 4°C with R073 Abs or 3F4 mAbs, and then chased 
for 45 min at either 4 or 37°C. After fixing and permeabiliz- 
ing the cells, the pattern of PrP Ab internalization was exam- 
ined by  immunofluorescence  (Fig.  7  B).  After  the  37°C 
chase,  GPI-anchored  wtPrP  either  remained  on  the  cell 
surface  or  was  internalized  to  a  compartment  near  the 
surface; whereas,  CD4PrP was internalized to the perinu- 
clear region. Thus, CIMPrP  c seems to differ from its GPI- 
anchored counterpart both by its plasma membrane distribu- 
tion and by its internalization pattern (Keller et al.,  1992). 
CD4PrP  c Is Soluble in Cold Triton X-IO0 
The purpose of the chimeric CD4PrP  was to remove PrP 
from the cholesterol-rich, Triton X-100 insoluble microen- 
vironment with which GPI anchored PrP  c  associates.  We 
employed Triton X-100 solubility to ascertain that the chi- 
meric protein was indeed not associated with these microdo- 
mains (Brown and Rose, 1992; Cerneus et al., 1993). First, 
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internalization of GPI- and CDgl-anchored 
PrP.  ScN2a cells were incubated  at 
4°C  with R073 antiserum  (,4  and  B) 
and ScN2a cells expressing CD4HM2- 
PrP with 3F4 mAb (C and D), and then 
chased for 45 min at 4°C (A and C) or 
370C (B and D).  The cells were then 
fixed, permeabilized, and the PrP Abs 
revealed by immunofluorescence. While 
GPI-anchored PrP  c either remained on 
the plasma membrane or was internal- 
ized within a shallow compartment, the 
CD4PrP accumulated in the perinuclear 
region. 
we verified that the solubility of GPI-linked wtPrP  c in Tri- 
ton X-100  is  temperature-dependent.  ScN2a cells were ra- 
diolabeled for 2 h, and then lysed in 1% Triton X-100 at ei- 
ther 4°C (Fig.  8, lane 1) or 370C (lane 2) or at 4°C in 1% 
Triton X-100 supplemented with 1% saponin (lane 3). The 
lysates were centrifuged at 39,000 g for 30 min at either 4°C 
or 25°C and the supernatants were analyzed by immunopre- 
cipitation and SDS-PAGE.  As expected,  PrP  c was relatively 
insoluble in Triton X-100 at 4°C, and saponin increased its 
solubility  arguing  that  PrP  c  is  bound  to  cholesterol-rich 
domains  (Cerneus  et  al.,  1993).  In  contrast to  the  GPI- 
anchored PrP  c,  CD4PrP  c  was  solubilized  equally  well  at 
4°C and at 37°C (lanes  4 and 5),  confirming that the re- 
combinant protein  is  not associated  with  cholesterol-rich 
complexes. 
We found that ultracentrifugation at 39,000 g for 30 min 
was  essential to detect the differential  insolubility of PrP  c 
in cold Triton X-100.  These  sedimentation conditions are 
more extreme than those used for MDCK cells and suggest 
that the cholesterol and glycolipid rich microdomains de- 
rived  from  N2a cells  are  either  smaller  or more buoyant 
than those from MDCK cells (Brown and Rose,  1992). 
Because  earlier  studies  showed  that  the  formation  of 
PrP  s~ is inhibited by brefeldin A  (BFA) (Taraboulos et al., 
1992), we examined the effect of  BFA on the compartmental- 
ization of PrP  c. When ScN2a cells were radiolabeled in the 
presence of BFA (5 #g/ml), PrP  c solubility was found to be 
similar at 4°C and at 370C. These results and the finding that 
the solubilization of PrP  c was unaltered by saponin (Fig.  8, 
lanes  6-8),  suggest that  nascent  PrP  c  molecules  synthe- 
sized in the presence of BFA did not associate to the choles- 
terol-rich  environment.  Therefore,  as  in  the  case  of the 
CD4PrP chimera, we observed a correlation between associ- 
ation of PrP  c  with  Triton X-100 insoluble membrane do- 
mains,  and  the  ability  of this  PrP  c  to  be  converted into 
prps  ~. 
Discussion 
In cells infected with prions, PrP  c has two different meta- 
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ity of wtPrP and CIMPrP in 
Triton  X-100. Untransfected 
ScNza cells (lanes 1-3,  6-8) 
and  ScN2a ceils  transfeeted 
with the CD4PrP gene (lanes 
4-5)  were  radiolabeled  for 
2 h,  and  then  lysed  in  1% 
Triton  X-100 either  at  37"C 
(lanes  2,  5,  and  6)  or  at 
4°C  (lanes 1,  4,  and  7),  or 
at 4"C in 1% Triton X-100 + 
1% saponin (lanes 3 and 8). In 
lanes 6--8, BFA (5/~g/ml) was 
included in the  labeling me- 
dium. The lysates were centri- 
fuged (39,000 g, 30 mill), and 
PrP was immunopurified  from 
the supernatants with either R073 (lanes 1-3,  6-8) or 3F4 (lanes 4 and 5). wtMoPrP was almost insoluble in Triton X-100 at 4°C (lane 
1) while CD4PrP was as soluble at 4°C as it was at 37°C. 
bolic  fates  which  are  mutually  exclusive.  A  minority of 
PrP  c molecules undergoes a conformational change to be- 
come PrP  s~ while most of the PrP  c is degraded through a 
pathway which is indistinguishable from that found in unin- 
fected cells. Our results suggest that both metabolic fates in- 
volve events mediated by membranes which are rich in cho- 
lesterol. 
Multiple lines of experimentation point to relationship be- 
tween cholesterol-dependent pathways and the metabolism 
of PrP,  First,  PrP  s~ synthesis was substantially reduced in 
cells  treated  with  lovastatin  while  PrP  c  levels  were  un- 
changed or increased. Since addition of cholesterol together 
with lovastatin prevented inhibition of PrP  s~ synthesis, we 
surmise that lovastatin exerted its effect through depletion of 
other mevalonate metabolites. While mevalonate is an ob- 
ligate precursor for all isoprenoids, studies have shown that 
sterols are far more sensitive to reduced mevalonate concen- 
tration. To provide for non-sterol isoprenoid synthesis, we 
added 200/~M mevalonate to all lovastatin-treated cells in 
our experiments. Second, replacing the GPI anchor of PrP 
with the CIM transmembrane domain targeted it to clathrin- 
coated pits and reduced the conversion of PrP  c into PrP  so. 
Since truncated PrP  c lacking the GPI anchor addition sig- 
nal can be converted into PrP  s~ but at a  diminished level 
(Kitamoto et al., 1993; Rogers et al., 1993), we surmise that 
the failure of CIMPrP  c to be transformed into CD4PrP  s~ is 
likely  to  result  from  its  targeting  to  clathrin-coated pits 
instead of cholesterol-rich membrane domains.  It will be 
important  to  examine  additional  amino  acid  sequences 
which are known to target proteins to clathrin-coated pits in 
order to  determine whether it  is  the targeting or altered 
conformation that  prevents  PrP  s~  formation,  Third,  tem- 
perature-dependent solubility in Triton X-100 confirmed the 
association  of GPI-anchored  PrP  c  with  cholesterol-  and 
glycolipid-rich complexes, in contrast to CD4PrP  c.  Since 
the  degradation  intermediate  of PrP  c  was  also  GPI  an- 
chored to these complexes, as judged by its differential solu- 
bility in Triton X-100 and its releasability with PIPLC, it ap- 
pears  that  the  first  step  in  PrP  c  degradation  takes  place 
within these cholesterol-rich complexes. Fourth, PrP  c deg- 
radation was  diminished  in  cells deprived of cholesterol. 
Fifth, that cholesterol-rich complexes are involved in PrP  s~ 
synthesis is suggested by the finding that BFA, known to in- 
hibit  PrP  s~  formation  in  ScN2a  cells  (Taraboulos  et  al., 
1992),  prevented the  association  of PrP  c  with  detergent- 
insoluble complexes. The failure of PrP  c to associate with 
cholesterol-rich domains may provide a mechanism to ac- 
count for the inhibition of PrP  s" formation by BFA. 
PrP  c Degradation 
Studies of the turnover of PrP  c are of considerable impor- 
tance with respect to prion diseases since diminished expres- 
sion in gene targeted mice prolongs incubation times (Biieler 
et al.,  1993;  Prusiner et al.,  1993)  while overexpression 
shortens them (Carlson et al., 1994; Prusiner et al.,  1990). 
In older mice overexpression of wtPrP transgenes produced 
spongiform degeneration of the CNS, a necrotizing myopa- 
thy of skeletal muscle, a demyelinating peripheral neuropa- 
thy and spontaneous formation of prion infectivity (Westa- 
way  et  al.,  1994).  Results  from cell  culture  studies  are 
consistent  with  earlier  investigations  which  identified  an 
NH2-terminaUy truncated molecule labeled prpc-II in ex- 
tracts  and  partially  purified fractions  from the  brains  of 
Syrian hamsters (Haraguchi et al.,  1989; Pan et al.,  1992). 
SHaPrpc-H  was  thought  to  be  generated  by  enzymatic 
cleavage of PrP  c  at a  site specific for a  protease with the 
specificity of chymotrypsin. For MoPrpc-A present in N2a 
cells (Borchelt et al., 1992; Westaway et al., 1987), the most 
likely cleavage point for a protease with chymotrypsin-like 
activity is Tyrt2s since chymotrypsin cleaves preferentially 
on the carboxyl site of Tyr, Trp, or Phe. Tyro28  is conserved 
in all known species studied, to date (Gabriel et al.,  1992). 
It is interesting to note that in the chicken PrP sequence, the 
substitution of Phe in position 109 (numbered according to 
SHaPrP) (Harris et al.,  1991) provides an additional cleav- 
age site for chymotrypsin-like proteases in this region, and 
that  cleavage at  this  site  has  been  reported  in  N~a  cells 
transfected with chicken PrP (Harris et al.,  1993).  These 
findings taken together argue that it is likely that a chymo- 
tryptic protease initiates the degradation of PrP  c by excis- 
ing  a  ~9-kD  fragment  from  the  NH2-terminus  of PrP  c 
resulting in the formation of prpc-II. 
Although  the  first  degradation  step  of PrP  c  seems  to 
occur  within  detergent  insoluble  membrane  complexes, 
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internalization  remains  to  be  determined.  At  present,  it 
is  unknown  whether  proteases  specific  for  cholesterol- 
dependent pathways participate in PrP  c degradation.  Sev- 
erai GPI-anchored peptidases have been described (Deddish 
et al.,  1990;  Hooper et al.,  1990). The presence of these 
peptidases in rafts suggests that other proteases, such as a 
putative  prpc-cleaving  enzyme,  may  also  be  present  in 
these membrane domains.  Since CD4PrP  c is not GPI an- 
chored, it seems likely that the degradation of this protein 
will differ from that of wtPrP  c. Several studies have shown 
that  GPI-anchored  molecules  are  endocytosed  through 
different pathways than their transmembrane counterparts 
(Keller et ai.,  1992; Yanagishita,  1992). 
Whether prpc-II can be converted into a truncated form 
of PrP  s" is unknown, prpc-II appears to lack the first puta- 
tive or-helical domain (H1, codons 109-122)  which is likely 
to be necessary for PrP  s~ formation (Gasset et ai.,  1992). 
Of note are two familial prion diseases where the patients ac- 
cumulated  truncated PrP  s~ molecules within PrP amyloid 
plaques but in each case these proteins contained the H1 re- 
gion (Kitamoto et al., 1993; Tagliavini et ai., 1991). A trun- 
cated PrP gene was constructed in which the signal peptide 
(codons 1-22) was fused to codons 90-254 to produce a pro- 
tein similar in length to PrP 27-30 which contains HI. In 
ScN2a cells this truncated PrP did acquire the protease re- 
sistance which is a hallmark of PrP  s~ (Rogers et ai.,  1993). 
Studies are in progress to determine if a molecule the size 
of prpc-II can acquire protease resistance in cultured cells 
and support scrapie infectivity in transgenic mice. 
Do Cholesterol-Rich Domains Play a Role in the 
Formation of PrPsc ? 
The  formation  of PrP  s~  is  a  posttranslational  process  in 
which PrP  s~ combines with PrP  c to form a transient com- 
plex (Prusiner et al.,  1990; Scott et al.,  1993). The conver- 
sion of PrP  c into PrP  s~ involves a profound conformational 
change where the primary event seems to be the acquisition 
of a structure rich in B-sheet (Pan et al.,  1993).  PrP  s~ ap- 
pears to serve as a  "template" for the conversion of PrP  c 
which may explain, at least in part, the apparent diversity of 
prions which has often been referred to as "strains." Whether 
each strain represents a distinct conformer of PrP  s~ which 
exhibits a  particular incubation time and pattern of PrP  s~ 
deposition in a specific host remains to be established (Carl- 
son et al.,  1994; DeArmond et al.,  1993; Prusiner,  1991). 
Our results argue that PrP  s~ formation occurs in cholesterol- 
rich, detergent-insoluble domains that contain GPI-anchored 
PrP  c. The insolubility of PrP  s~ in nondenaturing detergents 
such as Triton X-100 (Meyer et al.,  1986) has precluded 
demonstrating  attachment  of PrP  s~  in  these  cholesterol- 
rich, detergent-insoluble domains.  The presumed transient 
nature of the prpc/prP  s~ complexes may also make detec- 
tion of PrP  s~ in this compartment difficult. While immuno- 
electron microscopy has localized PrP  s~ primarily to lyso- 
somes in cultured cells, we cannot rule out the possibility of 
small amounts of PrP  s~ in other compartments (McKinley 
et al.,  1991). 
Whether or not cholesterol-rich membrane domains pro- 
mote the formation of PrP  s~ by concentrating PrP  c to high 
surface density remains to be established.  Caveolar GPI- 
anchored folate receptor is  very densely packed:  30,000 
molecules//~m  2 in MA104 cells (Rothberg et ai.,  1990a). If 
cholesterol-rich domains were to concentrate GPI-anchored 
PrP  c either on the plasma membrane or in other sites, they 
could provide a propitious environment for the formation of 
PrP  s~.  Alternatively, cholesterol-rich domains might func- 
tion by targeting PrP  c to other compartments where PrP  s~ 
is  formed.  Of  note,  an  extensive  caveolar  recycling  of 
cholesterol-rich domains from the PM to the TGN is likely 
to exist, since transport of the influenza HA to the PM pro- 
ceeds in MDCK cells even when the viral infection halts the 
synthesis of endogenous proteins (Wandinger-Ness et al., 
1990).  In the case of the folate receptor, caveolae are en- 
gaged in the recycling of this GPI-anchored protein before 
becoming acidified (Anderson et al.,  1992). It is interest- 
ing to note that PrP  s~ formation is insensitive to lysosomo- 
tropic amines (Caughey et ai., 1991; Taraboulos et al., 1992) 
whereas  receptor-mediated  folate  uptake  is  inhibited  by 
NI-LC1. 
Subcellular Sites of PrP  sc Formation 
The studies described here coupled with earlier reports be- 
gin to refine our view of PrP  s~ formation at the subcellular 
level. It seems likely that PrP  s~ is formed in a compartment 
bounded by cholesterol-rich, detergent-insoluble membrane 
domains.  Whether these domains might anchor other pro- 
teins that facilitate the conversion of PrP  c into PrP  s~ is un- 
known (Raeber et ai.,  1992). Considerable evidence argues 
that the  conversion of PrP  c  into  PrP  s~  involves the  post- 
translational unfolding and refolding of PrP into a  patho- 
genic conformer (Pan et al.,  1993). Attempts to identify a 
chemical event that triggers the acquisition of  this pathogenic 
conformation have been unrewarding, to date (Stahl et al., 
1993).  Transgenetic  studies  argue that  the  production of 
PrP  s~  requires  formation  of an  intermediate  complex  in 
which PrP  s~ and PrP  c interact (Prusiner et ai.,  1990; Scott 
et al.,  1993). The results of other transgenic mouse studies 
argue  that  an  additional  host  protein  participates  in  the 
generation of PrP  s~ (Telling et al.,  1994). 
Whether the subcellular compartment(s) in which PrP  s~ 
is formed is the  same in which the initial degradation of 
PrP  c to a 17-kD polypeptide (prpc-II) occurs remains to be 
established. That both the formation of PrP  s~ and the initial 
degradation of PrP  c occur in the same non-acidic compart- 
mentbounded by cholesterol-rich membranes is an attractive 
hypothesis that warrants further study.  Since the formation 
of PrP  s~ uses full-length PrP  c, such a compartment would 
be a metabolic branch point where the fate of PrP  c is deter- 
mined. 
The minimal formation of CD4PrP  s~ is in accord with the 
low levels of truncated PrP  s~ which appears to lack a GPI 
anchor (Rogers et al.,  1993). These results taken together 
with the inhibition of PrP  s~ formation by cholesterol deple- 
tion support the hypothesis that GPI anchorage, probably 
functioning in concert with cholesterol-dependent pathways, 
is  instrumental  in  the  formation of PrP  s~  in  ScN2a  cells. 
Such conclusions must be tempered by the results of studies 
which suggest that GPI-anchored proteins may not be con- 
stitutively bound to caveolae, but rather associate with these 
structures when multimerized,  for instance,  with divalent 
antibodies (Mayor et al., 1994). Since the PrP antibodies are 
divalent, it is possible that the behavior of PrP  c displayed in 
Fig. 3 was induced by cross-linking with ct-PrP antibodies. 
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nalized differently under the conditions of the experiments 
than  chimeric  CD4PrP  c  which  was  targeted  to  clathrin- 
coated pits. 
It seems likely that as the roles of caveolae and cholesterol- 
rich membranous microdomains become better understood, 
new tools will become available to decipher the subcellular 
events that feature in prion replication. If PrP  s~ is formed in 
a single subcellular compartment, then isolation of those or- 
ganelles might facilitate development of a system for the in 
vitro formation of PrP  s~ and the identification of proteins 
which function in this process (Telling et al.,  1994). 
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